SunTrust analyst Edward Nash raised his price target on Bluebird Bio to $232 after yesterday's NEJM publication of interim data from the HGB-204 and HGB-205 studies supporting his belief that "all patients in the HGB-207 study have the potential to achieve transfusion independence". The analyst adds that based on the publication, he has "dialed up his eligible beta-thalassemia patient numbers for LentiGlobil" given the prevalence of beta-thalassemia in the U.S. and E.U. of 15,000 cases, yielding an estimate of addressable market at 7,875 vs. his prior view of 2,650. Nash keeps his Buy rating on Bluebird Bio.